Eloxx Pharmaceuticals Q3 net loss widens on higher costs
ELOX•Eloxx Pharmaceuticals reported a third-quarter net loss of $5.54 million, with higher research and development and general and administrative costs driving the wider loss. The company expects cash and cash equivalents to fund operations into 2028.
1. Quarterly results
Eloxx Pharmaceuticals reported a Q3 net loss of $5.54 million, a loss per basic share of $0.49 and operating expenses of $5.95 million. Higher research and development costs reflected the initiation of the Phase 2b EXACT study and increased personnel costs; general and administrative costs rose on higher professional fees, personnel and facility costs. Higher interest income followed increased cash balances after a June 2026 public offering.




